In Brief: OTC labeling
This article was originally published in The Tan Sheet
OTC labeling: Protocol for FDA's upcoming consumer comprehension study on analgesic alcohol warning label statements should be released by the agency for public comment, the Aspirin Foundation of America suggests in July 22 comments to the agency. FDA announced its plans to conduct alcohol warning and statement of identity label comprehension studies in a May Federal Register notice ("The Tan Sheet" June 2, p. 8). AFA asks that the alcohol warnings message be "appropriate to both the product and the risk" and be designed "to avoid unnecessarily frightening persons who use aspirin to prevent heart attacks or strokes away from the medication." Bayer endorses the association's comments...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC